10/8/2009

Novartis acquired exclusive global rights to PTK 0796, Paratek Pharmaceuticals' treatment for methicillin-resistant Staphylococcus aureus and other drug-resistant bacteria. The drug is in Phase III trials and has shown promise in safety and tolerability.

Full Story:
Reuters

Related Summaries